Human Poliovirus
A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Viral Pathogens".
Deadline for manuscript submissions: 20 January 2025 | Viewed by 19799
Special Issue Editors
Interests: antivirals; vaccines; poliovirus eradication; enterovirus treatment; influenza vaccination program development in LMICs; coronavirus vaccines; hepatitis B&C elimination
Interests: influenza virus epidemiology; vaccine effectiveness; observational studies; methods to overcome vaccine hesitancy; polio eradication; immune responses to vaccines and infection; immunization against polio; measles; rubella; immunization; vaccines; viral surveillance; animal surveillance
Special Issue Information
Dear Colleagues,
Human polioviruses are the cause of poliomyelitis, a highly infectious disease that most commonly affects children under the age of 5. Polioviruses are spread from person to person, typically through the fecal–oral route and less frequently through contaminated water. Most people who become infected with poliovirus do not develop symptoms. Approximately a quarter of infections result in flu-like symptoms lasting two to five days. In 0.1–0.5% of cases, poliovirus will infect the nervous system, and in some instances, lead to paralysis. Death occurs in 2 to 10% of paralyzed cases. Post-polio syndrome (weakness, muscle pain, or paralysis) can develop in those that recover from infection decades after the initial infection. Although there is no cure, there are safe and effective vaccines used to immunize over 2.5 billion children worldwide and antivirals in development to stop virus excretion in immune-deficient individuals. In 1988, the World Health Assembly adopted a resolution for the worldwide eradication of polio. Of the three polio serotypes, as of 2020, only wild poliovirus type 1 remains in two countries: Pakistan and Afghanistan. Wild poliovirus types 2 and 3 have been certified as eradicated. On the other hand, circulating vaccine-derived polioviruses (cVDPV), which have mutated and regained both the neurovirulence and transmissibility properties of wild polioviruses, are now causing outbreaks in many countries and are an impediment to achieving the final goal of the eradication of polio.
This Special Issue is focused on the progress made in the eradication of poliovirus including the innovations in the development of antivirals and safer vaccines, improved surveillance, and vaccination campaigns. We invite you to submit original articles and review articles related to the above topics. This Special Issue will provide new knowledge about the advances that have been made that will help us reach our goal of polio eradication.
Dr. Mark A. McKinlay
Prof. Dr. Walter A. Orenstein
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- poliovirus
- vaccination
- eradication
- surveillance
- antivirals
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.